Table 4.
Cox Regression Analysis of Baseline Parameters and OS
| Parameter | Univariate Cox regression, HR (95%CI) |
p-value | Multivariate Cox regression, HR (95%CI) |
p-value |
|---|---|---|---|---|
| PSMA-ligand PET parameters | ||||
| Number of lesions | 1.38 [1.24–1.53] | < 0.001 | ||
| TTV | 1.27 [1.18–1.37] | < 0.001 | 1.15 [1.04–1.27] | 0.008 |
| ITLV | 1.24 [1.16–1.33] | < 0.001 | ||
| Highest SUVmax | 1.12 [0.97–1.29] | 0.139 | ||
| Whole-body SUVmax | 0.96 [0.79–1.17] | 0.711 | ||
| Whole-body SUVmean | 0.78 [0.55–1.09] | 0.148 | ||
| Whole-body SUVpeak | 0.98 [0.81–1.19] | 0.849 | ||
| Pretherapeutic clinical parameters | ||||
| Age | 1.0 [0.98–1.02] | 0.988 | ||
| Time since initial diagnosis | 0.75 [0.65–0.88] | < 0.001 | 0.85 [0.71–1.02] | 0.089 |
| Prior chemotherapy | 1.56 [1.11–2.23] | 0.012 | 1.10 [0.75–1.65] | 0.63 |
| Liver metastases | 2.07 [1.05–3.68] | 0.021 | 0.89 [0.41–1.83] | 0.747 |
| Visceral metastases | 1.77 [1.18–2.58] | 0.004 | 1.76 [1.04–2.87] | 0.028 |
| PSA | 1.17 (1.091–1.250) | < 0.001 | 0.98 [0.9–1.07] | 0.684 |
| AP | 1.56 (1.365–1.779) | < 0.001 | 1.14 (0.941–1.367) | 0.173 |
| LDH | 2.21 (1.801–2.651) | < 0.001 | 1.42 (1.032–1.921) | 0.026 |
| Hb | 0.7 (0.631–0.774) | < 0.001 | 0.86 (0.761–0.907) | 0.015 |
All continuous parameters except age and Hb were log (base2) transformed. Significant P-values are given in bold. OS = overall survival; HR = hazard ratio; CI = confidence interval; PSMA = prostatespecific membrane antigen; PET = positron emission tomography; TTV = total tumor volume; ITLV = intensity-weighted lesion volume; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; SUVpeak = peak standardized uptake value, PSA = prostate-specific antigen; AP = alkaline phosphatase; LDH = lactate dehydrogenase; Hb = hemoglobin